From: Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Pt # | Age | Race | ER or PR + | # prior lines tx | # met sites | Trastuzumab in prior regimen (days since) | Prior Lapatinib | # injections | PFS (d) | OS (d) |
---|---|---|---|---|---|---|---|---|---|---|
001 | 45 | W | Y | 4 | 2 | Y (23) | N | 4 | 53 | 615+ |
002 | 50 | W | Y | 3 | 3 | Y (34) | P | 6 | 82 | 484 |
003 | 48 | W | N | 3 | 4 | Y (24) | C | 6 | 85 | 596+ |
004 | 53 | W | N | 6 | 1 | N | C | 6 | 86 | 549+ |
005 | 63 | W | Y | 2 | 2 | N | C | 4 | 48 | 540+ |
006 | 60 | W | N | 5 | 4 | Y (37) | C | 6 | 86 | 531+ |
007 | 46 | B | N | 4 | 1 | Y (33) | P | 5 | 69 | 486+ |
008 | 65 | W | N | 8 | 3 | Y (27) | C | 3 | 41 | 456+ |
012 | 55 | W | N | 3 | 2 | N | C | 5 | 69 | 216 |
013 | 65 | W | N | 4 | 2 | Y (27) | C | 4 | 55 | 316+ |
014 | 56 | W | N | 3 | 2 | Y (25) | C | 12 | 188 | 310+ |
015 | 46 | B | Y | 3 | 4 | Y (21) | N | 4 | 69 | 274+ |
Median | 54 | Â | Â | 3.5 | 2 | Â | Â | 5 | 69 | Â |